Study lung cancer biology and why immunotherapy stops working
Part of Cancer, Lungs & breathing clinical trials.
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of lung cancer from pathology or blood tests
- You have never received any anti-cancer treatment before starting the study
- You do not have another active cancer at the same time or within the past 5 years
- You have not joined another treatment study and received research drugs or devices in the last 4 weeks
- You do not have an active autoimmune disease needing whole-body treatment in the last 2 years
- You have not taken whole-body immune-suppressing medicines or steroid tablets in the last 7 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This study looks at immune cells inside lung tumors to better understand how they work. If you are having surgery for a thoracic tumor, your tissue could help researchers learn more.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.